Q-omics provides the consensus-scored CAPN8 profile across patient tissues and cancer cell-line models. CAPN8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAPN8 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CAPN8 RNA expression shows 20,419 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where CAPN8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN8 survival associations across molecular data types. CAPN8 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN8 RNA expression–survival associations across cancer types. High CAPN8 expression shows unfavorable associations in KIRC, KIRP, LUSC and ACC, but favorable associations in BLCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAPN8 RNA expression.
This table summarizes CAPN8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CAPN8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN8 shows lower tumor expression in KIRC and LUSC and higher tumor expression in THCA, LIHC, PAAD and CHOL. The KIRC box plot shows higher CAPN8 RNA expression in normal versus tumor tissue (log2 FC = −0.845, t-test p < 0.001).
This table shows molecular features associated with CAPN8 in patient tissues and cancer cell lines. In patient samples, CAPN8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
